Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1096.8
(0.16%)
INR 1096.8
(0.16%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 450.71 Billion INR | 12.99% |
| 2022 | 398.89 Billion INR | 17.59% |
| 2021 | 339.21 Billion INR | 0.2% |
| 2020 | 338.53 Billion INR | 17.03% |
| 2019 | 289.27 Billion INR | 9.35% |
| 2018 | 264.54 Billion INR | 25.37% |
| 2017 | 211.01 Billion INR | 29.86% |
| 2016 | 162.49 Billion INR | 2.07% |
| 2015 | 159.2 Billion INR | 24.26% |
| 2014 | 128.12 Billion INR | 35.01% |
| 2013 | 94.89 Billion INR | 30.48% |
| 2012 | 72.72 Billion INR | 16.6% |
| 2011 | 62.37 Billion INR | 6.22% |
| 2010 | 58.72 Billion INR | 22.56% |
| 2009 | 47.91 Billion INR | 13.37% |
| 2008 | 42.26 Billion INR | 16.29% |
| 2007 | 36.34 Billion INR | 3.65% |
| 2006 | 35.06 Billion INR | 30.38% |
| 2005 | 26.89 Billion INR | 26.28% |
| 2004 | 21.29 Billion INR | 14.14% |
| 2003 | 18.65 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 439.23 Billion INR | 0.0% |
| 2023 Q4 | 450.71 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 450.71 Billion INR | 12.99% |
| 2022 FY | 398.89 Billion INR | 17.59% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 371.66 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 398.89 Billion INR | 0.0% |
| 2021 Q4 | 339.21 Billion INR | 0.0% |
| 2021 FY | 339.21 Billion INR | 0.2% |
| 2021 Q2 | 340.16 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 338.53 Billion INR | 0.0% |
| 2020 FY | 338.53 Billion INR | 17.03% |
| 2020 Q2 | 304.87 Billion INR | 0.0% |
| 2019 Q2 | 272.89 Billion INR | 0.0% |
| 2019 FY | 289.27 Billion INR | 9.35% |
| 2019 Q4 | 289.27 Billion INR | 0.0% |
| 2018 FY | 264.54 Billion INR | 25.37% |
| 2018 Q2 | 241.69 Billion INR | 0.0% |
| 2018 Q4 | 264.54 Billion INR | 0.0% |
| 2017 Q4 | 211.01 Billion INR | 0.0% |
| 2017 FY | 211.01 Billion INR | 29.86% |
| 2017 Q2 | 199.77 Billion INR | 0.0% |
| 2016 FY | 162.49 Billion INR | 2.07% |
| 2016 Q2 | 157.8 Billion INR | 0.0% |
| 2016 Q4 | 162.49 Billion INR | 0.0% |
| 2015 Q2 | 148.32 Billion INR | 0.0% |
| 2015 Q4 | 159.2 Billion INR | 0.0% |
| 2015 FY | 159.2 Billion INR | 24.26% |
| 2014 Q2 | 114.88 Billion INR | 0.0% |
| 2014 Q4 | 128.12 Billion INR | 0.0% |
| 2014 FY | 128.12 Billion INR | 35.01% |
| 2013 Q2 | 82.9 Billion INR | 0.0% |
| 2013 Q4 | 94.89 Billion INR | 0.0% |
| 2013 FY | 94.89 Billion INR | 30.48% |
| 2012 Q4 | 72.72 Billion INR | 0.0% |
| 2012 FY | 72.72 Billion INR | 16.6% |
| 2011 Q4 | 62.37 Billion INR | 0.0% |
| 2011 FY | 62.37 Billion INR | 6.22% |
| 2010 FY | 58.72 Billion INR | 22.56% |
| 2009 FY | 47.91 Billion INR | 13.37% |
| 2008 FY | 42.26 Billion INR | 16.29% |
| 2007 FY | 36.34 Billion INR | 3.65% |
| 2006 FY | 35.06 Billion INR | 30.38% |
| 2005 FY | 26.89 Billion INR | 26.28% |
| 2004 FY | 21.29 Billion INR | 14.14% |
| 2003 FY | 18.65 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | -599.262% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -1481.228% |
| Granules India Limited | 55.2 Billion INR | -716.368% |
| Indoco Remedies Limited | 21.44 Billion INR | -2001.5% |
| Achyut Healthcare Limited | 309.52 Million INR | -145516.499% |
| Ajanta Pharma Limited | 46.38 Billion INR | -871.706% |
| Alkem Laboratories Limited | 155.74 Billion INR | -189.386% |
| Alpa Laboratories Limited | 1.82 Billion INR | -24580.26% |
| Brooks Laboratories Limited | 904.45 Million INR | -49732.838% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -4080.921% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -5790.717% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -3613.047% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | -16.308% |
| Eris Lifesciences Limited | 70.48 Billion INR | -539.418% |
| FDC Limited | 24.68 Billion INR | -1726.17% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | -213.899% |
| Gufic Biosciences Limited | 10.92 Billion INR | -4025.382% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -3768.446% |
| Ipca Laboratories Limited | 111.01 Billion INR | -306.003% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -20662.818% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -25196.246% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -29774.659% |
| Laurus Labs Limited | 83.87 Billion INR | -437.395% |
| Lupin Limited | 239.97 Billion INR | -87.82% |
| Mankind Pharma Limited | 119.63 Billion INR | -276.75% |
| Medicamen Biotech Limited | 2.94 Billion INR | -15203.254% |
| Medico Remedies Limited | 961.95 Million INR | -46754.171% |
| Megasoft Limited | 3.65 Billion INR | -12217.996% |
| NATCO Pharma Limited | 69.06 Billion INR | -552.614% |
| Piramal Pharma Limited | 153.11 Billion INR | -194.358% |
| RPG Life Sciences Limited | 5.12 Billion INR | -8688.096% |
| Sigachi Industries Limited | 6.94 Billion INR | -6392.99% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 47.262% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -1899.547% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -11038.011% |
| Unichem Laboratories Limited | 31.69 Billion INR | -1322.108% |
| Wanbury Limited | 3.43 Billion INR | -13021.518% |
| Windlas Biotech Limited | 6.26 Billion INR | -7097.553% |
| ZIM Laboratories Limited | 4.46 Billion INR | -9987.122% |
| Zydus Lifesciences Limited | 292.8 Billion INR | -53.929% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -8651.07% |
| Divi's Laboratories Limited | 154.7 Billion INR | -191.348% |
| Hester Biosciences Limited | 6.62 Billion INR | -6704.818% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -5573.94% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -12185.394% |
| Bal Pharma Limited | 3.2 Billion INR | -13967.746% |
| Strides Pharma Science Limited | 58.39 Billion INR | -671.805% |
| Venus Remedies Limited | 6.26 Billion INR | -7090.388% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -1645.537% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -1957.068% |
| Shilpa Medicare Limited | 30.93 Billion INR | -1357.114% |
| Aarti Drugs Limited | 24.32 Billion INR | -1752.995% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -1908.176% |
| Suven Life Sciences Limited | 2.84 Billion INR | -15719.966% |
| Ind-Swift Limited | 6.54 Billion INR | -6786.705% |
| Valiant Laboratories Limited | 3.42 Billion INR | -13052.372% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -1028.444% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -1817.153% |
| Themis Medicare Limited | 5.66 Billion INR | -7857.309% |
| Hikal Limited | 24.87 Billion INR | -1712.182% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | -199.26% |
| Sequent Scientific Limited | 15.4 Billion INR | -2825.992% |
| Novartis India Limited | 9.24 Billion INR | -4772.964% |
| Wockhardt Limited | 76.49 Billion INR | -489.247% |
| Jubilant Pharmova Limited | 115.48 Billion INR | -290.28% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -95628.389% |
| Neuland Laboratories Limited | 18.32 Billion INR | -2359.482% |
| Morepen Laboratories Limited | 12.93 Billion INR | -3385.256% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -18674.977% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -13417.768% |